Preventing Prostate Cancer with CDDO-Me in Mice
Author Information
Author(s): Gao Xiaohua, Deeb Dorrah, Liu Yongbo, Arbab Ali S., Divine George W., Dulchavsky Scott A., Gautam Subhash C.
Primary Institution: Henry Ford Health System
Hypothesis
Does CDDO-Me prevent the development and progression of prostate cancer in the TRAMP mouse model?
Conclusion
CDDO-Me significantly inhibits the progression of preneoplastic lesions to prostate cancer in TRAMP mice.
Supporting Evidence
- CDDO-Me inhibited the growth of prostate cancer cells by inducing apoptosis.
- Early intervention with CDDO-Me prevented the progression of preneoplastic lesions to adenocarcinoma.
- Delayed treatment with CDDO-Me also reduced the incidence of cancerous lesions.
Takeaway
Researchers found that a compound called CDDO-Me can help stop early signs of prostate cancer in mice, making it less likely for them to develop full-blown cancer.
Methodology
TRAMP mice were treated with CDDO-Me at different ages and doses to assess its effects on prostate cancer progression.
Limitations
The study did not explore the mechanism of CDDO-Me's anti-metastatic activity.
Participant Demographics
Male TRAMP mice were used in the study.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website